论文部分内容阅读
目的探讨胸腺肽α1对慢性肺原性心脏病(肺心病)急性加重期的治疗效果。方法100例肺心病急性加重期患者,其PaO2<60 mm Hg(1 mm Hg=0.133 kPa),按治疗药物分为胸腺肽α1组、普通胸腺肽组各50例。2组均予以常规化痰、平喘、抗生素治疗,在此基础上,胸腺肽α1组加用胸腺肽α1 1.6 mg皮下注射,隔日1次;普通胸腺肽组予5%葡萄糖溶液250 ml+普通胸腺肽30 mg静脉滴注,每日1次。分别比较2组患者PaO2升高至60 mm Hg时间、血常规恢复正常时间、呼吸道症状改善时间、2次住院间隔时间,以及治疗期间过敏反应、心原性肝损害发生率等。结果胸腺肽α1组、普通胸腺肽组患者PaO2升高至60 mm Hg的时间分别为(3±2)、(10±3)d(P<0.05),血常规恢复正常时间分别为(5±2)、(14±3)d(P<0.05),呼吸道症状改善时间分别为(3±1)、(10±3)d(P<0.05),2次住院间隔时间分别为(78±3)、(28±3)d(P<0.01);治疗期间发生过敏反应分别为2例(4.0%)、11例(22.0%)(P<0.05),心原性肝损害分别为6例(12.0%)、11例(22.0%)(P>0.05)。结论胸腺肽α1对肺心病急性加重期患者的临床疗效优于普通胸腺肽。
Objective To investigate the therapeutic effect of thymosin α1 on acute exacerbation of chronic pulmonary heart disease (pulmonary heart disease). Methods 100 cases of acute exacerbation of pulmonary heart disease patients PaO2 <60 mm Hg (1 mm Hg = 0.133 kPa), according to the treatment of drugs divided into thymosin α1 group, 50 cases of the ordinary thymosin group. On the basis of this, thymosin α1 group was treated with subcutaneous injection of thymosin α1 1.6 mg subcutaneously once every other day; common thymosin group was treated with 250 ml 5% dextrose solution and 30 mg intravenous thymosin Drip, once daily. PaO2 was increased to 60 mm Hg time, blood routine recovery time, respiratory symptoms improvement time, two hospitalization intervals, and allergic reactions during treatment, the incidence of cardiogenic liver damage were compared between the two groups. Results The PaO2 raised to 60 mm Hg in the thymosin α1 group and the normal thymosin group were (3 ± 2) and (10 ± 3) days (P <0.05), and the blood routine recovery time was (5 ± 2) , (14 ± 3) d (P <0.05). The time of improvement of respiratory symptoms were (3 ± 1) and (10 ± 3) d (28 ± 3) d (P <0.01). Allergic reactions occurred in 2 cases (4.0%) and 11 cases (22.0% ), 11 cases (22.0%) (P> 0.05). Conclusion The clinical efficacy of thymosin α1 in patients with acute exacerbation of pulmonary heart disease is better than that of common thymosin.